Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGiNAUT phase 2b study of AZD8965 in idiopathic pulmonary fibrosis
CTR20262970Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AZD8965 in idiopathic pulmonary fibrosis (IPF), sponsored by AstraZeneca. Started Jul 2026; status: active.
02
Drugs
AZD8965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20262970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262970.